Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Solid Tumor
Clinical trial register · United States · industry-sponsored

Solid Tumor Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 11 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
California 45 Texas 33 Florida 32 New York 31 Massachusetts 25
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Novartis Pharmaceuticals3 PAQ Therapeutics, Inc.2 Biohaven Therapeutics Ltd.2 I-Mab Biopharma US Limited2 Astellas Pharma Inc2
State
California45 Texas33 Florida32 New York31 Massachusetts25
All 43 states
Target enrolment
to

Solid Tumor trials in the USA

80 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Gilead Sciences
Phase 1
302
Michigan, Texas
2026-07-17
Recruiting
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
NCT07517198Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Phase 1
40
California, Texas, Utah
2026-04-13
Recruiting
I-Mab Biopharma US Limited
Phase 2
180
Arizona, California, Massachusetts
2026-02-11
Recruiting
Axcynsis Therapeutics Pte Ltd
Phase 1
83
Oregon
2026-01-14
Recruiting
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
NCT07300150Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Solid Tumor
DrugCetuximab
PAQ Therapeutics, Inc.
Phase 1
210
Massachusetts, Texas, Utah, Virginia
2025-11-21
Recruiting
ITM Solucin GmbH
Phase 1
20
California, Ohio, Pennsylvania, Texas
2025-09-26
Recruiting
Rise Therapeutics LLC
Phase 1
33
Colorado, Tennessee
2025-08-01
Recruiting
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
NCT07094204Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
DrugPanitumumab
Astellas Pharma Inc
Phase 1
364
California, Georgia, Louisiana, Michigan, Missouri, New Jersey, New York, Ohio
2025-07-25
Recruiting
STORM Therapeutics LTD
Phase 1/2
107
California, Florida, Massachusetts, Michigan, New York, Ohio, Texas, Virginia
2025-05-05
Recruiting
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
NCT06952010Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor
DrugZanzalintinib
Exelixis
Phase 1
303
California, Connecticut, Florida, Massachusetts, Missouri, New York, North Carolina, Tennessee
2025-05-01
Recruiting
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
NCT06810544Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor
DrugAbemaciclib
Tango Therapeutics, Inc.
Phase 1/2
191
Arizona, California, District of Columbia, Florida, Illinois, Massachusetts, Minnesota, New York
2025-03-24
Recruiting
Biohaven Therapeutics Ltd.
Phase 1
140
California, Colorado, Florida, Michigan, North Carolina, Ohio, South Carolina, Tennessee
2025-03-20
Recruiting
Jabez Bioscience, Inc
Phase 1
25
Ohio, Utah
2025-03-17
Recruiting
Lamassu Bio Inc
Phase 1/2
70
Ohio
2025-03-10
Recruiting
PAQ Therapeutics, Inc.
Phase 1
300
California, Massachusetts, Michigan, Tennessee, Texas, Utah, Virginia
2024-12-19
Active, closed
GlaxoSmithKline
Phase 1/2
14
California, Colorado, Michigan, New York, Pennsylvania
2024-12-13
Recruiting
Corbus Pharmaceuticals Inc.
Phase 1/2
156
Alabama, Arizona, California, Colorado, Florida, Illinois, Minnesota, Nebraska
2024-12-04
Recruiting
Genentech, Inc.
Phase 1
410
California, Colorado, Connecticut, Florida, Illinois, Massachusetts, Michigan, New York
2024-11-14
Recruiting
Pierre Fabre Medicament
Phase 1/2
140
District of Columbia, Ohio, Tennessee
2024-10-22
Recruiting
Yuhan Corporation
Phase 1/2
201
Virginia
2024-10-02
Recruiting
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NCT06586957Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor
DrugsDoxorubicin·Paclitaxel
NiKang Therapeutics, Inc.
Phase 1
238
Arkansas, California, Colorado, Florida, Georgia, Kansas, Massachusetts, New Jersey
2024-09-19
Recruiting
Sumitomo Pharma America, Inc.
Phase 1/2
120
California, Colorado, Florida, Illinois, Ohio, Tennessee, Texas, Washington
2024-08-14
Recruiting
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
NCT06401356Hematologic Malignancy, Solid Tumor, Advanced Malignancies
DrugPelabresib
Novartis Pharmaceuticals
Phase 3
50
California, Florida, Illinois, Michigan, New York
2024-08-13
Recruiting
Step Pharma, SAS
Phase 1
70
Florida, Texas
2024-08-02
Recruiting
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
NCT06452160Mesothelioma, Epithelioid Hemangioendothelioma(EHE), Solid Tumor
BridGene Biosciences Inc.
Phase 1
103
Texas
2024-06-27
Recruiting
Proviva Therapeutics, Inc.
Phase 1
26
California, Florida, Nebraska
2024-06-11
Recruiting
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
NCT06425926Melanoma Stage IV, Solid Tumor
Georgiamune Inc
Phase 1/2
117
Arizona, California, Massachusetts, Montana, New York, Ohio, Tennessee, Virginia
2024-05-09
Recruiting
Biohaven Therapeutics Ltd.
Phase 1/2
500
California, District of Columbia, Florida, Georgia, Michigan, Missouri, New York, Oklahoma
2024-04-22
Active, closed
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
NCT06105021Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor
Affini-T Therapeutics, Inc.
Phase 1/2
100
California, Connecticut, New York, Oregon, Tennessee, Texas, Washington, Wisconsin
2024-03-06
Recruiting
Alyssum Therapeutics
Phase 1/2
100
Arizona, California, New York, Oregon, Texas
2024-02-13
Recruiting
OnCusp Therapeutics, Inc.
Phase 1
263
Colorado, Connecticut, Florida, Massachusetts, Michigan, New York, Oklahoma, Tennessee
2024-02-09
Active, closed
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
NCT06160752Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma
Tyra Biosciences, Inc
Phase 1
40
California, Massachusetts, Ohio, Texas
2023-11-22
Recruiting
Qualigen Theraputics, Inc.
Phase 1
54
Arizona, Connecticut, Michigan, Texas
2023-11-01
Recruiting
BeOne Medicines
Phase 1
337
California, Connecticut, Florida, Michigan, New Jersey, New York, Oregon, Texas
2023-09-21
Recruiting
ImmunoGenesis
Phase 1
105
Arizona, California, Florida, Kentucky, Louisiana, Missouri, Pennsylvania, Texas
2023-09-07
Active, closed
Abbisko Therapeutics Co, Ltd
Phase 1
169
California, Michigan, Nevada, Ohio
2023-06-26
Recruiting
Chugai Pharmaceutical
Phase 1
209
Pennsylvania, Rhode Island, Tennessee, Texas, Virginia
2023-05-24
Recruiting
FOG-001 in Locally Advanced or Metastatic Solid Tumors
NCT05919264Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor
DrugsLonsurf·MFOLFOX6·Trifluridine/Tipiracil·Avastin
Parabilis Medicines, Inc.
Phase 1/2
619
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Maryland, Massachusetts
2023-05-23
Active, closed
Study of PYX-106 in Solid Tumors
NCT05718557Solid Tumor
Pyxis Oncology, Inc
Phase 1
47
Arizona, California, Colorado, Georgia, Illinois, Massachusetts, Ohio, Rhode Island
2023-05-23
Active, closed
Gilead Sciences
Phase 1
182
Washington
2023-05-11
Active, closed
A2 Biotherapeutics Inc.
Phase 1/2
160
Arizona, California, Florida, Minnesota, Missouri, New York, Texas
2023-04-28
Active, closed
DEKA Biosciences
Phase 1
39
California, New York, Oklahoma, Texas, Virginia
2023-04-03
Recruiting
Teligene US
Phase 2
60
California, Texas
2023-03-16
Recruiting
A Study of PYX-201 in Advanced Solid Tumors
NCT05720117Solid Tumor, Advanced Solid Tumor
DrugPYX-201
Pyxis Oncology, Inc
Phase 1
330
Arizona, California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri
2023-03-14
Recruiting
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
NCT05784688Solid Tumor, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
DrugsTU2218·Keytruda·Pembrolizumab
TiumBio Co., Ltd.
Phase 1/2
140
Texas, Washington
2023-03-10
Active, closed
Klus Pharma Inc.
Phase 2
240
Indiana, Kentucky, Maryland, Minnesota, New York, Texas, Virginia
2023-01-17
Active, closed
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
NCT05653882Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck
DrugsEtakafusp alfa·Keytruda·Pembrolizumab
Asher Biotherapeutics, Inc.
Phase 1
552
California, Connecticut, Florida, Illinois, Massachusetts, Michigan, Missouri, New Jersey
2023-01-04
Recruiting
Sanofi
Phase 1/2
542
Delaware, Iowa, Kansas, Michigan, New Jersey, New York, Rhode Island, Texas
2022-11-29
Active, closed
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
NCT05544552Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma
DrugTYRA-300
Tyra Biosciences, Inc
Phase 1/2
310
Massachusetts, New York, North Carolina, Ohio, Tennessee, Washington
2022-11-22
Active, closed
Jazz Pharmaceuticals
Phase 1
98
California, Colorado, Florida, Illinois, New York, Oklahoma, Pennsylvania, Tennessee
2022-10-10
Recruiting
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
NCT05245500Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor
DrugNavlimetostat
Bristol-Myers Squibb
Phase 1
336
Arizona, Colorado, Florida, Illinois, Massachusetts, Michigan, Minnesota, New Jersey
2022-06-09
Recruiting
Astellas Pharma Inc
Phase 1
681
California, Colorado, Connecticut, District of Columbia, Florida, Kansas, Massachusetts, Michigan
2022-06-08
Recruiting
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
NCT05076760Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer
DrugsOpdivo·Docetaxel·Nivolumab
Memgen, Inc.
Phase 1
40
Florida, North Carolina
2022-04-21
Recruiting
Impact Therapeutics, Inc.
Phase 1/2
61
New Jersey, New York, South Carolina, Texas
2022-02-11
Active, closed
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
NCT05199272Solid Tumor, Clear Cell Renal Cell Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer
23andMe, Inc.
Phase 1/2
141
California, Georgia, Michigan, New York, Oregon, Tennessee, Texas, Virginia
2021-12-29
Recruiting
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
NCT05176483Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
DrugsZanzalintinib·Relatlimab·Yervoy·Ipilimumab
Exelixis
Phase 1
1,394
Arizona, California, Colorado, Connecticut, Delaware, Florida, Illinois, Indiana
2021-12-14
Active, closed
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
NCT05163028Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
HUYABIO International, LLC.
Phase 1
42
California, Florida, Ohio, Texas, Virginia
2021-12-13
Active, closed
MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment
NCT05219734Cancer, Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer
Invitae Corporation
Observational
400
Indiana, North Carolina
2021-11-29
Active, closed
A Study of NDI 1150-101 in Patients With Solid Tumors
NCT05128487Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer
DrugPembrolizumab
Nimbus Saturn, Inc.
Phase 1/2
106
Arizona, Connecticut, District of Columbia, Florida, Kentucky, Maryland, Michigan, Minnesota
2021-11-05
Recruiting
Simcha IL-18, Inc.
Phase 1/2
316
Arizona, Colorado, Connecticut, Florida, Massachusetts, New York
2021-08-06
Recruiting
RAPA-201 Therapy of Solid Tumors
NCT05144698Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity
DrugsRAPA·Pembrolizumab
Rapa Therapeutics LLC
Phase 1/2
37
New Jersey
2021-08-01
Recruiting
Novartis Pharmaceuticals
Phase 1/2
222
Alabama, California, Florida, Illinois, Iowa, Michigan, Minnesota, Missouri
2021-07-30
Active, closed
Presage Biosciences
Early Phase 1
15
Louisiana, New York, North Carolina, Ohio, Oregon, Pennsylvania, South Carolina, Washington
2021-07-26
Recruiting
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
NCT04900818Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer
DrugGivastomig
I-Mab Biopharma US Limited
Phase 1
330
California, Colorado, Indiana, Massachusetts, New Jersey, New York, North Carolina, Tennessee
2021-06-29
Active, closed
IDEAYA Biosciences
Phase 1
169
Arizona, Arkansas, California, Florida, Indiana, Maryland, Massachusetts, New York
2021-04-14
Active, closed
TH1902 in Patients With Advanced Solid Tumors
NCT04706962Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer
Theratechnologies
Phase 1
70
Michigan, Pennsylvania, Texas
2021-03-04
Active, closed
Intra-IMMUSG Pte Ltd
Phase 2
51
Arizona, California, Kentucky, Nevada
2020-12-12
Recruiting
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
NCT04516447Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
DrugsAzenosertib·Pegylated liposomal doxorubicin·Gemcitabine·Paclitaxel
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1
172
Colorado, Massachusetts, Missouri, New York, North Carolina, Rhode Island, Tennessee, Texas
2020-10-26
Active, closed
Daiichi Sankyo
Phase 1
40
New York, Ohio
2020-10-09
Recruiting
ImmVira Pharma Co. Ltd
Phase 1/2
30
Arizona, Massachusetts, Pennsylvania, Texas, Virginia
2020-09-17
Recruiting
Eisai Inc.
Phase 1/2
182
Arizona, Arkansas, California, Florida, Georgia, Illinois, Kentucky, Maryland
2020-08-06
Recruiting
Inhibrx Biosciences, Inc
Phase 1/2
340
California, Florida, Georgia, Illinois, Iowa, Kentucky, Michigan, Minnesota
2019-12-10
Active, closed
Idera Pharmaceuticals, Inc.
Phase 2
30
Arizona, California, Texas
2019-10-29
Recruiting
Trial of DFP-14927 in Advanced Solid Tumors
NCT03943004Solid Tumor, Cancer
Delta-Fly Pharma, Inc.
Phase 1
30
California, Texas
2019-09-30
Recruiting
Oxford BioTherapeutics Ltd
Phase 1
200
Arizona, California, Florida, Iowa, Kentucky, Mississippi, New Mexico, New York
2019-07-25
Active, closed
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
NCT03647163Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma, Renal Cell Carcinoma (RCC)
DrugsVSV-IFNβ-NIS·Ipilimumab·Nivolumab·Pembrolizumab
Vyriad, Inc.
Phase 1/2
33
Minnesota, Ohio
2019-04-09
Recruiting
Dabrafenib and/or Trametinib Rollover Study
NCT03340506Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
100
Arizona, Maryland, Ohio, Texas
2018-01-26
Active, closed
Genentech, Inc.
Phase 1
200
Massachusetts, New York, Tennessee
2016-12-13
Active, closed
Eli Lilly and Company
Phase 1
223
Kentucky, New York, Texas
2016-11-21
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
370
Colorado, Illinois, Massachusetts, New York, North Dakota, South Dakota, Texas
2015-03-19
Rows per page Showing 1–80 of 80
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/solid-tumor

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 11 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 80 of those studies listing the condition Solid Tumor.

How many Solid Tumor trials are recruiting in the US?

55 of the 80 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 25 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Solid Tumor), 80 studies
PhaseStudiesRecruitingShare
Phase 1433053.8%
Phase 1/2282135%
Phase 2526.3%
Early Phase 1101.3%
Observational101.3%
Phase 3111.3%
Phase 4111.3%

Most active sponsors

Lead sponsors with the most studies (Solid Tumor)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals33
Astellas Pharma Inc22
Biohaven Therapeutics Ltd.22
Exelixis22
Genentech, Inc.21
Gilead Sciences21
I-Mab Biopharma US Limited22
PAQ Therapeutics, Inc.22
Pyxis Oncology, Inc21
Tyra Biosciences, Inc20

Top states

Top states (Solid Tumor), by number of studies with a site there
StateStudies
California45
Texas33
Florida32
New York31
Massachusetts25
Arizona22
Michigan22
Colorado19
Ohio18
Tennessee16
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.